Cytosorbents Corp (NASDAQ:CTSO) CFO Kathleen P. Bloch sold 12,400 shares of the business’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $7.75, for a total transaction of $96,100.00. Following the completion of the transaction, the chief financial officer now directly owns 241,038 shares in the company, valued at $1,868,044.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of Cytosorbents Corp (NASDAQ:CTSO) traded down $0.40 on Wednesday, reaching $7.40. 114,401 shares of the company’s stock traded hands, compared to its average volume of 134,665. The company has a quick ratio of 3.17, a current ratio of 3.36 and a debt-to-equity ratio of 0.73. The firm has a market cap of $212.32, a PE ratio of -19.47 and a beta of -0.54. Cytosorbents Corp has a 12 month low of $3.30 and a 12 month high of $7.90.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). Cytosorbents had a negative net margin of 67.83% and a negative return on equity of 233.72%. sell-side analysts anticipate that Cytosorbents Corp will post -0.27 EPS for the current fiscal year.

CTSO has been the topic of several recent research reports. B. Riley set a $11.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research note on Friday, December 22nd. ValuEngine raised shares of Cytosorbents from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Cytosorbents in a research note on Tuesday, November 21st. Finally, Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research note on Thursday, December 21st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $10.60.

A number of institutional investors and hedge funds have recently made changes to their positions in CTSO. Fortaleza Asset Management Inc. increased its stake in Cytosorbents by 81.6% in the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after buying an additional 10,500 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after purchasing an additional 22,500 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in shares of Cytosorbents during the 3rd quarter worth $365,000. Finally, Skylands Capital LLC boosted its position in shares of Cytosorbents by 45.1% during the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock worth $4,716,000 after purchasing an additional 225,558 shares in the last quarter. 8.65% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Cytosorbents Corp (CTSO) CFO Kathleen P. Bloch Sells 12,400 Shares” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/17/cytosorbents-corp-ctso-cfo-kathleen-p-bloch-sells-12400-shares.html.

About Cytosorbents

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Insider Buying and Selling by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.